Merck & Co (MRK) Stock Price

Merck & Co Price

NYSE·CLOSED
131.84USD+1.64 (+1.25 %)
Market closed

Revenue has compounded at 5.7% per year over the past 19 years to 64.93 B USD. Earnings per share have grown at 7.0% per year over the last 19 years. Merck & Co's net margin stands at 28.1%, up from 26.8% several years earlier. Merck & Co currently offers a dividend yield of about 2.49%. The payout ratio is around 45% of earnings. The dividend has grown at 4.1% per year over the past 19 years. Analysts set a median price target of 121.89 USD, implying 7.5% below the current price. Of 34 analysts, 21 rate the stock a buy — an overall Buy consensus. The stock trades about 70% above its 52-week low.

Merck & Co stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Merck & Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Merck & Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Merck & Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Merck & Co Stock Price History
DateMerck & Co Price
8/3/2026131.84 USD
7/31/2026130.20 USD
7/30/2026129.79 USD
7/29/2026131.29 USD
7/27/2026131.97 USD
7/23/2026130.48 USD
7/22/2026127.47 USD
7/21/2026126.26 USD
7/20/2026124.40 USD
7/17/2026127.50 USD
7/16/2026127.63 USD
7/15/2026123.61 USD
7/14/2026120.78 USD
7/13/2026123.64 USD
7/10/2026123.54 USD
7/9/2026125.07 USD
7/8/2026127.10 USD
7/7/2026128.86 USD
7/6/2026126.50 USD
7/2/2026129.56 USD
7/1/2026125.37 USD
6/30/2026128.50 USD
6/29/2026128.72 USD
6/26/2026128.66 USD
6/25/2026125.45 USD
6/24/2026120.60 USD
6/23/2026119.60 USD
6/22/2026113.57 USD
6/18/2026112.10 USD
6/17/2026115.32 USD
6/16/2026114.11 USD
6/15/2026116.15 USD
6/12/2026120.97 USD
6/11/2026120.97 USD
6/10/2026117.72 USD
6/9/2026119.60 USD
6/8/2026119.52 USD
6/5/2026122.05 USD
6/4/2026118.38 USD
6/3/2026115.79 USD
6/2/2026115.61 USD
6/1/2026115.04 USD
5/29/2026118.71 USD
5/28/2026120.49 USD
5/27/2026121.62 USD
5/26/2026120.69 USD
5/22/2026121.29 USD
5/21/2026114.57 USD
5/20/2026114.03 USD
5/19/2026114.24 USD
5/18/2026112.56 USD
5/15/2026111.38 USD
5/14/2026113.41 USD
5/13/2026113.45 USD
5/12/2026112.37 USD
5/11/2026111.28 USD
5/8/2026111.38 USD
5/7/2026112.30 USD
5/6/2026113.56 USD
5/5/2026113.15 USD
5/4/2026113.11 USD
5/1/2026112.16 USD
4/30/2026109.18 USD
4/29/2026110.95 USD
4/28/2026110.03 USD
4/27/2026110.23 USD
4/24/2026111.90 USD
4/23/2026114.62 USD
4/22/2026112.89 USD
4/21/2026112.56 USD
4/20/2026117.10 USD
4/17/2026119.07 USD
4/16/2026115.46 USD
4/15/2026117.90 USD
4/14/2026119.96 USD
4/13/2026120.15 USD
4/10/2026121.42 USD
4/9/2026122.68 USD
4/8/2026123.18 USD
4/7/2026119.28 USD
4/6/2026120.85 USD
4/2/2026120.87 USD
4/1/2026120.84 USD
3/31/2026120.29 USD
3/30/2026118.10 USD
3/27/2026119.63 USD
3/26/2026118.93 USD
3/25/2026119.37 USD
3/24/2026116.37 USD
3/23/2026115.68 USD
3/20/2026114.18 USD
3/19/2026114.20 USD
3/18/2026114.50 USD
3/17/2026115.87 USD
3/16/2026115.43 USD
3/13/2026115.61 USD
3/12/2026115.91 USD
3/11/2026116.21 USD
3/10/2026117.09 USD
3/9/2026117.11 USD
3/6/2026115.79 USD
3/5/2026116.07 USD
3/4/2026120.28 USD
3/3/2026119.83 USD
3/2/2026121.41 USD
2/27/2026123.82 USD
2/26/2026119.30 USD
2/25/2026122.46 USD
2/24/2026123.93 USD
2/23/2026123.82 USD
2/20/2026122.26 USD
2/19/2026121.86 USD
2/18/2026121.66 USD
2/17/2026121.57 USD
2/13/2026121.41 USD
2/12/2026119.24 USD
2/11/2026119.31 USD
2/10/2026117.15 USD
2/9/2026117.65 USD
2/6/2026121.93 USD
2/5/2026119.75 USD
2/4/2026118.33 USD
2/3/2026115.84 USD
2/2/2026113.37 USD
1/30/2026110.27 USD
1/29/2026108.34 USD
1/28/2026106.90 USD
1/27/2026107.92 USD
1/26/2026107.40 USD
1/23/2026108.18 USD
1/22/2026109.18 USD
1/21/2026111.11 USD
1/20/2026109.45 USD
1/16/2026108.83 USD
1/15/2026110.97 USD
1/14/2026111.01 USD
1/13/2026108.26 USD
1/12/2026109.19 USD
1/9/2026110.53 USD
1/8/2026110.99 USD
1/7/2026108.60 USD
1/6/2026108.87 USD
1/5/2026107.44 USD
1/2/2026106.45 USD
12/31/2025105.26 USD
12/30/2025106.06 USD
12/29/2025106.62 USD
12/26/2025106.78 USD
12/24/2025106.45 USD
12/23/2025105.04 USD
12/22/2025104.72 USD
12/19/2025101.09 USD
12/18/2025100.69 USD
12/17/202599.18 USD
12/16/202598.27 USD
12/15/2025100.26 USD
12/12/2025100.30 USD
12/11/202599.01 USD
12/10/202597.62 USD
12/9/202596.89 USD
12/8/202598.93 USD
12/5/202599.72 USD
12/4/2025100.89 USD
12/3/2025102.27 USD
12/2/2025101.03 USD
12/1/2025101.83 USD
11/28/2025104.83 USD
11/26/2025104.63 USD
11/25/2025105.66 USD
11/24/2025100.40 USD
11/21/202597.76 USD
11/20/202594.97 USD
11/19/202595.05 USD
11/18/202596.43 USD
11/17/202592.86 USD
11/14/202592.92 USD
11/13/202592.93 USD
11/12/202591.45 USD
11/11/202590.95 USD
11/10/202586.75 USD
11/7/202586.28 USD
11/6/202585.78 USD
11/5/202584.39 USD
11/4/202583.86 USD
11/3/202582.49 USD
10/31/202585.98 USD
10/30/202586.28 USD
10/29/202586.58 USD
10/28/202587.03 USD
10/27/202588.00 USD
10/24/202587.49 USD
10/23/202587.18 USD
10/22/202587.61 USD
10/21/202587.62 USD
10/20/202586.32 USD
10/17/202584.79 USD
10/16/202583.92 USD
10/15/202584.11 USD
10/14/202584.70 USD
10/13/202585.70 USD
10/10/202585.99 USD
10/9/202587.50 USD
10/8/202586.40 USD
10/7/202587.61 USD
10/6/202588.80 USD
10/3/202589.19 USD
10/2/202589.51 USD
10/1/202590.13 USD
9/30/202583.93 USD
9/29/202578.58 USD
9/26/202578.56 USD
9/25/202577.60 USD
9/24/202579.67 USD
9/23/202579.96 USD
9/22/202580.40 USD
9/19/202581.51 USD
9/18/202581.53 USD
9/17/202581.14 USD
9/16/202581.09 USD
9/15/202581.02 USD
9/12/202582.81 USD
9/11/202585.15 USD
9/10/202584.03 USD
9/9/202584.61 USD
9/8/202584.09 USD
9/5/202584.71 USD
9/4/202584.05 USD
9/3/202584.18 USD
9/2/202585.48 USD
8/29/202584.12 USD
8/28/202583.21 USD
8/27/202584.07 USD
8/26/202584.99 USD
8/25/202585.31 USD
8/22/202587.37 USD
8/21/202586.08 USD
8/20/202584.66 USD
8/19/202584.93 USD
8/18/202584.22 USD
8/15/202584.21 USD
8/14/202582.76 USD
8/13/202582.71 USD
8/12/202580.30 USD
8/11/202580.03 USD
8/8/202580.69 USD
8/7/202580.37 USD
8/6/202579.44 USD
8/5/202580.79 USD
8/4/202579.86 USD
Access this data via the Eulerpool API
Get Free API Key

Merck & Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
60.12 B USD
2.95 B USD
365.00 M USD
Jan 1, 2024
64.17 B USD
20.22 B USD
17.12 B USD
Jan 1, 2025
64.93 B USD
23.49 B USD
18.25 B USD
Jan 1, 2026 (e)
66.80 B USD
26.90 B USD
6.96 B USD
Jan 1, 2027 (e)
70.18 B USD
28.26 B USD
24.07 B USD
Jan 1, 2028 (e)
74.53 B USD
30.02 B USD
26.55 B USD
Jan 1, 2029 (e)
74.29 B USD
29.92 B USD
25.49 B USD
Jan 1, 2030 (e)
73.99 B USD
29.80 B USD
24.59 B USD

Merck & Co Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 3, 2026, 1:10 PM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITB USD
EBIT MARGIN%
NET INCOMEB USD
NET INCOME GROWTH%
DIV.USD
DIV. GROWTH%
SHARESB
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
39.5039.8140.1242.2939.1241.5248.7059.2860.1264.1764.9366.8070.1874.5374.2973.99
-6.480.780.795.41-7.506.1317.3121.721.406.741.182.895.056.21-0.33-0.41
62.1964.7567.8268.0669.2967.2072.0270.6373.1776.3271.9871.9871.9871.9871.9871.98
24.5625.7827.2128.7927.1127.9035.0841.8743.9948.9846.7348.0850.5153.6453.4753.25
7.555.506.808.937.936.3213.9718.282.9520.2223.4926.9028.2630.0229.9229.80
19.1113.8116.9421.1220.2615.2228.6830.844.9131.5136.1740.2740.2740.2740.2740.27
4.443.922.396.229.847.0713.0514.520.3717.1218.256.9624.0726.5525.4924.59
-62.73-11.75-38.93159.8258.25-28.2084.6511.27-97.494,589.596.64-61.87245.7810.31-4.00-3.52
1.811.851.891.992.262.482.642.802.963.123.283.403.603.80––
2.262.212.165.2913.579.736.456.065.715.415.133.665.885.56––
2.812.782.722.632.562.542.542.552.552.542.492.492.492.492.492.49
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Merck & Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Merck & Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Merck & Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Merck & Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Merck & Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Merck & Co stock margins

The Merck & Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Merck & Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Merck & Co.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
72.02 %
28.68 %
26.79 %
Jan 1, 2022
70.63 %
30.84 %
24.49 %
Jan 1, 2023
73.17 %
4.91 %
0.61 %
Jan 1, 2024
76.32 %
31.51 %
26.68 %
Jan 1, 2025
71.98 %
36.17 %
28.12 %
Jan 1, 2026 (e)
71.98 %
40.27 %
10.42 %
Jan 1, 2027 (e)
71.98 %
40.27 %
34.30 %
Jan 1, 2028 (e)
71.98 %
40.27 %
35.62 %

Merck & Co Stock Revenue, EBIT, Earnings per Share

The Merck & Co earnings per share therefore indicates how much revenue Merck & Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
19.21 USD
5.51 USD
5.15 USD
Jan 1, 2022
23.27 USD
7.18 USD
5.70 USD
Jan 1, 2023
23.54 USD
1.16 USD
0.14 USD
Jan 1, 2024
25.25 USD
7.96 USD
6.74 USD
Jan 1, 2025
26.10 USD
9.44 USD
7.34 USD
Jan 1, 2026 (e)
26.65 USD
10.81 USD
2.78 USD
Jan 1, 2027 (e)
27.99 USD
11.36 USD
9.60 USD
Jan 1, 2028 (e)
29.73 USD
12.06 USD
10.59 USD

Merck & Co business model & stock analysis

The company Merck & Co Inc has a long history. It was founded in 1891 by the German pharmacist Friedrich Jacob Merck and is now based in Kenilworth, New Jersey, USA. The company has evolved over time into a globally operating company in the pharmaceutical and chemical industry. Merck & Co Inc's business model is based on the development, production, and marketing of medicines and products for the healthcare industry. The company collaborates with other partners such as universities, other companies, and governments to achieve the best possible scientific progress. Research and development play a very important role in this. Merck is divided into three main areas: The Human Health division, which specializes in the development of prescription drugs and products to improve human health. The second division is Animal Health, which focuses on animal medicines and care products. The third division, Life Science (formerly MilliporeSigma), is dedicated to the development of products and services for biopharmaceutical research and production to facilitate the discovery and manufacturing of medicines. Merck & Co Inc. offers a wide range of products, ranging from prescription medicines to specialty chemicals. Some of the most well-known drugs include Januvia for the treatment of type 2 diabetes and Keytruda, an immuno-oncology drug used in the treatment of various types of cancer. Other well-known drugs from Merck & Co Inc. include Gardasil for the prevention of HPV infections, Propecia for the treatment of male pattern hair loss, and Zetia for the treatment of high cholesterol. The company is extremely innovative and has made significant advances in pharmaceutical research in recent decades. Merck & Co Inc. has won numerous awards over the years, including the "2018 Australian Financial Review Boss Most Innovative Companies Award" and the "2018 Global Energy Award for Technology Innovation". Merck & Co Inc. operates worldwide and has subsidiaries and partnerships in many countries. The company has about 69,000 employees and distributes its products in over 140 countries. Merck & Co Inc.'s products are typically prescription-only and prescribed by doctors and professionals. Overall, Merck & Co Inc. is a company with an impressive history that is now one of the leading companies in the pharmaceutical and chemical industry. Thanks to its innovation and its consistent focus on the needs of patients and healthcare professionals, it is able to successfully meet challenges in the healthcare industry and set new standards.

Merck & Co SWOT Analysis

Strengths

Merck & Co Inc, a leading pharmaceutical company, possesses the following strengths:

  • Strong brand reputation and recognition worldwide
  • Extensive experience and expertise in drug development and research
  • Robust portfolio of patented drugs and intellectual property
  • Broad geographical presence, with operations in numerous countries
  • Diverse product offerings across multiple therapeutic areas

Merck & Co Inc faces the following weaknesses:

  • Dependency on a limited number of flagship drugs for significant revenue
  • Relatively high research and development costs
  • Vulnerability to generic competition as patents expire
  • Regulatory challenges and delays in drug approvals
  • Potential exposure to litigation related to product safety and side effects

Merck & Co Inc can explore the following opportunities:

  • Expansion into emerging markets with growing healthcare needs
  • Investment in research and development of innovative drugs and therapies
  • Strategic collaborations and partnerships for joint ventures and licensing
  • Advancements in technology for drug delivery and precision medicine
  • Increasing demand for personalized healthcare solutions

Merck & Co Inc faces the following threats:

  • Intense competition from other major pharmaceutical companies
  • Economic and political fluctuations impacting global markets
  • Stringent regulations and compliance requirements
  • Potential disruption caused by unforeseen events, such as pandemics
  • Negative public perception and skepticism towards the pharmaceutical industry

Weaknesses

Merck & Co Inc faces the following weaknesses:

  • Dependency on a limited number of flagship drugs for significant revenue
  • Relatively high research and development costs
  • Vulnerability to generic competition as patents expire
  • Regulatory challenges and delays in drug approvals
  • Potential exposure to litigation related to product safety and side effects

Merck & Co Inc can explore the following opportunities:

  • Expansion into emerging markets with growing healthcare needs
  • Investment in research and development of innovative drugs and therapies
  • Strategic collaborations and partnerships for joint ventures and licensing
  • Advancements in technology for drug delivery and precision medicine
  • Increasing demand for personalized healthcare solutions

Merck & Co Inc faces the following threats:

  • Intense competition from other major pharmaceutical companies
  • Economic and political fluctuations impacting global markets
  • Stringent regulations and compliance requirements
  • Potential disruption caused by unforeseen events, such as pandemics
  • Negative public perception and skepticism towards the pharmaceutical industry

Opportunities

Merck & Co Inc can explore the following opportunities:

  • Expansion into emerging markets with growing healthcare needs
  • Investment in research and development of innovative drugs and therapies
  • Strategic collaborations and partnerships for joint ventures and licensing
  • Advancements in technology for drug delivery and precision medicine
  • Increasing demand for personalized healthcare solutions

Merck & Co Inc faces the following threats:

  • Intense competition from other major pharmaceutical companies
  • Economic and political fluctuations impacting global markets
  • Stringent regulations and compliance requirements
  • Potential disruption caused by unforeseen events, such as pandemics
  • Negative public perception and skepticism towards the pharmaceutical industry

Threats

Merck & Co Inc faces the following threats:

  • Intense competition from other major pharmaceutical companies
  • Economic and political fluctuations impacting global markets
  • Stringent regulations and compliance requirements
  • Potential disruption caused by unforeseen events, such as pandemics
  • Negative public perception and skepticism towards the pharmaceutical industry

Merck & Co Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Merck & Co Employees
Details
Date
Merck & Co Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Merck & Co Segments

Merck & Co Revenue by Segment (1/3)

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

Other pharmaceutical
Keytruda
Gardasil/Gardasil 9
Janumet
Januvia
Gardasil
ProQuad/M-M-R II/Varivax
Zepatier
Isentress
Remicade
Pneumovax 23
Vytorin
Isentress/Isentress HD
Adempas
Implanon/Nexplanon
Cancidas
Nasonex
Cubicin
Zetia
Emend
Noxafil
Dulera
Primaxin
Temodar
Cosopt/Trusopt
Zostavax
Fosamax
Invanz
Bridion
Atozet
RotaTeq
NuvaRing
Remeron
Clarinex
Zocor
Propecia
PegIntron
Follistim AQ
Victrelis
Singulair
Cozaar/Hyzaar
Arcoxia
Simponi
Details
Date
Other pharmaceutical
Keytruda
Gardasil/Gardasil 9
Janumet
Januvia
Gardasil
ProQuad/M-M-R II/Varivax
Zepatier
Isentress
Remicade
Pneumovax 23
Vytorin
Maxalt
Pneumovax
Isentress/Isentress HD
Adempas
Implanon/Nexplanon
Cancidas
Nasonex
Cubicin
Zetia
Implanon
Emend
Noxafil
Dulera
Primaxin
Temodar
Cerazette
Cosopt/Trusopt
Zostavax
Claritin Rx
Fosamax
Invanz
Bridion
Atozet
Proscar
Integrilin
RotaTeq
Avelox
NuvaRing
Remeron
Vasotec/Vaseretic
Clarinex
Zocor
Asmanex
Propecia
PegIntron
Follistim AQ
Victrelis
Singulair
Cozaar/Hyzaar
Arcoxia
Simponi
Jan 1, 2012
0.00 USD
0.00 USD
0.00 USD
1.66 B USD
4.09 B USD
1.63 B USD
1.27 B USD
0.00 USD
1.52 B USD
2.08 B USD
0.00 USD
1.75 B USD
638.00 M USD
580.00 M USD
0.00 USD
0.00 USD
0.00 USD
619.00 M USD
1.27 B USD
0.00 USD
2.57 B USD
348.00 M USD
489.00 M USD
258.00 M USD
207.00 M USD
384.00 M USD
917.00 M USD
271.00 M USD
444.00 M USD
651.00 M USD
244.00 M USD
676.00 M USD
445.00 M USD
261.00 M USD
0.00 USD
217.00 M USD
211.00 M USD
601.00 M USD
201.00 M USD
623.00 M USD
232.00 M USD
192.00 M USD
393.00 M USD
383.00 M USD
185.00 M USD
424.00 M USD
653.00 M USD
468.00 M USD
502.00 M USD
3.85 B USD
1.28 B USD
453.00 M USD
331.00 M USD
Jan 1, 2014
0.00 USD
55.00 M USD
0.00 USD
2.07 B USD
3.93 B USD
1.74 B USD
1.39 B USD
0.00 USD
1.67 B USD
2.37 B USD
746.00 M USD
1.52 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
502.00 M USD
681.00 M USD
1.10 B USD
0.00 USD
2.65 B USD
0.00 USD
553.00 M USD
402.00 M USD
460.00 M USD
329.00 M USD
350.00 M USD
0.00 USD
257.00 M USD
765.00 M USD
0.00 USD
470.00 M USD
529.00 M USD
340.00 M USD
0.00 USD
0.00 USD
0.00 USD
659.00 M USD
0.00 USD
723.00 M USD
193.00 M USD
0.00 USD
232.00 M USD
258.00 M USD
0.00 USD
264.00 M USD
381.00 M USD
412.00 M USD
153.00 M USD
1.09 B USD
806.00 M USD
519.00 M USD
689.00 M USD
Jan 1, 2015
4.55 B USD
566.00 M USD
1.91 B USD
2.15 B USD
3.86 B USD
0.00 USD
1.51 B USD
0.00 USD
1.51 B USD
1.79 B USD
542.00 M USD
1.25 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
588.00 M USD
573.00 M USD
858.00 M USD
1.13 B USD
2.53 B USD
0.00 USD
535.00 M USD
487.00 M USD
536.00 M USD
313.00 M USD
312.00 M USD
0.00 USD
0.00 USD
749.00 M USD
0.00 USD
359.00 M USD
569.00 M USD
353.00 M USD
0.00 USD
0.00 USD
0.00 USD
610.00 M USD
0.00 USD
732.00 M USD
0.00 USD
0.00 USD
187.00 M USD
217.00 M USD
0.00 USD
183.00 M USD
182.00 M USD
383.00 M USD
0.00 USD
931.00 M USD
667.00 M USD
471.00 M USD
690.00 M USD
Jan 1, 2016
4.70 B USD
1.40 B USD
2.17 B USD
2.20 B USD
3.91 B USD
0.00 USD
1.64 B USD
555.00 M USD
1.39 B USD
1.27 B USD
641.00 M USD
1.14 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
606.00 M USD
558.00 M USD
537.00 M USD
1.09 B USD
2.56 B USD
0.00 USD
549.00 M USD
595.00 M USD
436.00 M USD
297.00 M USD
283.00 M USD
0.00 USD
0.00 USD
685.00 M USD
0.00 USD
284.00 M USD
561.00 M USD
482.00 M USD
0.00 USD
0.00 USD
0.00 USD
652.00 M USD
0.00 USD
777.00 M USD
0.00 USD
0.00 USD
0.00 USD
186.00 M USD
0.00 USD
0.00 USD
0.00 USD
355.00 M USD
0.00 USD
915.00 M USD
511.00 M USD
450.00 M USD
766.00 M USD
Jan 1, 2017
1.25 B USD
2.31 B USD
2.31 B USD
2.16 B USD
2.15 B USD
0.00 USD
1.68 B USD
1.66 B USD
0.00 USD
837.00 M USD
821.00 M USD
751.00 M USD
0.00 USD
0.00 USD
565.00 M USD
500.00 M USD
496.00 M USD
422.00 M USD
387.00 M USD
382.00 M USD
352.00 M USD
0.00 USD
342.00 M USD
309.00 M USD
287.00 M USD
280.00 M USD
271.00 M USD
0.00 USD
0.00 USD
246.00 M USD
0.00 USD
241.00 M USD
241.00 M USD
239.00 M USD
225.00 M USD
0.00 USD
0.00 USD
204.00 M USD
0.00 USD
197.00 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
174.00 M USD
0.00 USD
40.00 M USD
18.00 M USD
0.00 USD
0.00 USD

Merck & Co Revenue by Segment (2/3)

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Details
Date
Remicade and Simponi
Jan 1, 2012
0.00 USD
Jan 1, 2014
0.00 USD
Jan 1, 2015
0.00 USD
Jan 1, 2016
0.00 USD
Jan 1, 2017
0.00 USD

Merck & Co Revenue by Segment (3/3)

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

Operating segments
Pharmaceutical
Pharmaceutical segment
All Other
Other pharmaceutical
Other segments
Primary Care and Women's Health
Diversified Brands
Vaccines
Other
Oncology
Hospital and Specialty
Details
Date
Segment
Operating segments
Segment One
Pharmaceutical
Pharmaceutical segment
All Other Segments
All Other
Other pharmaceutical
Other segments
Primary Care and Women's Health
Diversified Brands
Vaccines
Other
Oncology
Hospital and Specialty
Other Miscellaneous
Jan 1, 2012
47.01 B USD
0.00 USD
40.60 B USD
0.00 USD
0.00 USD
6.41 B USD
0.00 USD
4.14 B USD
0.00 USD
638.00 M USD
192.00 M USD
580.00 M USD
0.00 USD
0.00 USD
211.00 M USD
254.00 M USD
Jan 1, 2014
0.00 USD
41.63 B USD
0.00 USD
36.04 B USD
0.00 USD
0.00 USD
5.59 B USD
4.78 B USD
0.00 USD
3.93 B USD
1.09 B USD
746.00 M USD
610.00 M USD
553.00 M USD
329.00 M USD
0.00 USD
Jan 1, 2015
0.00 USD
0.00 USD
0.00 USD
0.00 USD
313.00 M USD
0.00 USD
0.00 USD
0.00 USD
3.66 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2016
0.00 USD
0.00 USD
0.00 USD
0.00 USD
35.15 B USD
0.00 USD
0.00 USD
0.00 USD
3.86 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2017
0.00 USD
0.00 USD
0.00 USD
0.00 USD
35.39 B USD
0.00 USD
0.00 USD
0.00 USD
4.27 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Merck & Co Revenue by Region

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

United States
Int’l
Europe, Middle East and Africa
Europe, Middle East, and Africa
Asia Pacific
Latin America
Asia Pacific (other than China and Japan)
Asia Pacific (other than Japan and China)
Other Countries
Japan
China
Intu2019l
Details
Date
United States
Int’l
Europe, Middle East and Africa
Europe, Middle East, and Africa
Asia Pacific
Latin America
Asia Pacific (other than China and Japan)
Asia Pacific (other than Japan and China)
Other Countries
Japan
China
Intu2019l
Jan 1, 2018
18.21 B USD
24.08 B USD
12.21 B USD
0.00 USD
0.00 USD
2.42 B USD
0.00 USD
2.91 B USD
1.15 B USD
3.21 B USD
2.18 B USD
0.00 USD
Jan 1, 2019
20.33 B USD
26.52 B USD
12.71 B USD
0.00 USD
0.00 USD
2.47 B USD
0.00 USD
2.94 B USD
1.61 B USD
3.58 B USD
3.21 B USD
0.00 USD
Jan 1, 2020
21.03 B USD
26.97 B USD
13.60 B USD
0.00 USD
0.00 USD
2.27 B USD
2.86 B USD
0.00 USD
1.23 B USD
3.38 B USD
3.62 B USD
0.00 USD
Jan 1, 2021
22.43 B USD
26.28 B USD
13.34 B USD
0.00 USD
0.00 USD
2.21 B USD
2.41 B USD
0.00 USD
1.22 B USD
2.73 B USD
4.38 B USD
0.00 USD
Jan 1, 2022
27.21 B USD
32.08 B USD
14.49 B USD
0.00 USD
0.00 USD
2.58 B USD
3.61 B USD
0.00 USD
2.57 B USD
3.63 B USD
5.19 B USD
0.00 USD
Jan 1, 2023
28.48 B USD
31.64 B USD
13.25 B USD
0.00 USD
0.00 USD
3.09 B USD
3.23 B USD
0.00 USD
2.10 B USD
3.16 B USD
6.80 B USD
0.00 USD
Jan 1, 2024
32.28 B USD
31.89 B USD
14.04 B USD
0.00 USD
0.00 USD
3.46 B USD
3.06 B USD
0.00 USD
2.56 B USD
3.28 B USD
5.49 B USD
0.00 USD
Jan 1, 2025
36.51 B USD
28.50 B USD
14.58 B USD
0.00 USD
0.00 USD
3.41 B USD
0.00 USD
2.98 B USD
2.88 B USD
2.71 B USD
1.94 B USD
0.00 USD

Merck & Co Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Merck & Co historical P/E ratio, EBIT multiple, and P/S ratio

Merck & Co annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Merck & Co shares outstanding

The number of shares of Merck & Co was 2.49 B in 2025. This indicates how many shares Merck & Co is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
2.54 B Stocks
Jan 1, 2022
2.55 B Stocks
Jan 1, 2023
2.55 B Stocks
Jan 1, 2024
2.54 B Stocks
Jan 1, 2025
2.49 B Stocks
Jan 1, 2026 (e)
2.49 B Stocks
Jan 1, 2027 (e)
2.49 B Stocks
Jan 1, 2028 (e)
2.49 B Stocks

Merck & Co stock splits

In Merck & Co's history, there have been no stock splits.

Merck & Co Dividend History

37 years of dividend payments · 15 consecutive increases

YearAnnual DividendYoY ChangePayments
20260.85USDYTD—1×
Mar 16, 20260.85USD 0.0%1/1
20253.28USD↑ 5.1%4×
Mar 17, 20250.81USD 0.0%1/4
Jun 16, 20250.81USD 0.0%2/4
Sep 15, 20250.81USD 0.0%3/4
Dec 15, 20250.85USD↑ 4.9%4/4
20243.12USD↑ 5.4%4×
20232.96USD↑ 5.7%4×
20222.80USD↑ 6.1%4×
20212.64USD↑ 6.5%4×
20202.48USD↑ 9.7%4×
20192.26USD↑ 13.6%4×
20181.99USD↑ 5.3%4×
20171.89USD↑ 2.2%4×

Merck & Co dividend history and estimates

In 2025, Merck & Co paid a dividend amounting to 3.28 USD. Dividend means that Merck & Co distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
2.64 USD
0.00 USD
Jan 1, 2022
2.80 USD
0.00 USD
Jan 1, 2023
2.96 USD
0.00 USD
Jan 1, 2024
3.12 USD
0.00 USD
Jan 1, 2025
3.28 USD
0.00 USD
Jan 1, 2026 (e)
0.85 USD
2.55 USD
Jan 1, 2027 (e)
0.00 USD
3.60 USD
Jan 1, 2028 (e)
0.00 USD
3.80 USD

Merck & Co dividend payout ratio

In 2025, Merck & Co had a payout ratio of 44.71%. The payout ratio indicates the percentage of the company's profits that Merck & Co distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
51.29 %
Jan 1, 2022
49.14 %
Jan 1, 2023
2,071.32 %
Jan 1, 2024
46.32 %
Jan 1, 2025
44.71 %
Jan 1, 2026 (e)
122.45 %
Jan 1, 2027 (e)
37.45 %
Jan 1, 2028 (e)
35.90 %

Current Merck & Co forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
4.82 %
Buy
61.76 % (21)
Hold
38.24 % (13)
Sell
0.00 % (0)
12M Price Target
121.89
Last Price
130.14
Currency
USD
12M Return Potential
-6.34 %
LTM Return
0 %

Merck & Co Analyst Rating Actions

DateFirmActionRatingReliability
7/29/2026
Barclays
Barclays
MaintainedOverweight33
7/13/2026
JP Morgan
JP Morgan
MaintainedOverweight80
7/13/2026
Guggenheim
Guggenheim
MaintainedBuy30
7/13/2026
BMO Capital
BMO Capital
MaintainedOutperform–
7/9/2026
Morgan Stanley
Morgan Stanley
MaintainedEqual Weight60
7/8/2026
Wells Fargo
Wells Fargo
MaintainedOverweight56
7/8/2026
RBC Capital
RBC Capital
MaintainedOutperform52
7/6/2026
Cantor Fitzgerald
Cantor Fitzgerald
MaintainedNeutral44
6/30/2026
Scotiabank
Scotiabank
MaintainedSector Outperform75
6/30/2026
B of A Securities
B of A Securities
MaintainedBuy70

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Merck & Co Earnings Calls

2025
2024

Merck & Co Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/4/2026-0.28USD-16.58 BUSD-2026 Q2
4/30/2026-1.53USD-16.04 BUSD-2026 Q1
2/3/20262.03USD-16.36 BUSD-2025 Q4
4/25/20241.98USD-15.15 BUSD-2024 Q1
2/1/20240.13USD-14.66 BUSD-2023 Q4
8/1/20231.88USD-14.93 BUSD-2023 Q2
4/27/20231.78USD-14.35 BUSD-2023 Q1
2/2/20231.54USD-13.83 BUSD-2022 Q4
10/27/20221.72USD-14.29 BUSD-2022 Q3
7/28/20221.72USD-14.11 BUSD-2022 Q2
...

EESG©

Eulerpool ESG Scorecard© for the Merck & Co stock

73/100
79
Environment
88
Social
52
Governance
E

Environment

20
Scope 1 - Direct Emissions718,400
Scope 2 - Indirect emissions from purchased energy356,900
Scope 3 - Indirect emissions within the value chain6,184,100
Total CO₂ emissions1,075,300
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees51
Percentage of women in management—
Percentage of Asian employees18
Share of Asian management15
Percentage of Hispanic/Latino employees7
Hispano/Latino Management share6
Percentage of Black employees9
Black Management Share6
Percentage of white employees64
White Management Share71
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Merck & Co shareholder structure

% Name
9.00799%
BLACKROCK, INC.
BLACKROCK, INC.
6.42152%
VANGUARD CAPITAL MANAGEMENT LLC
VANGUARD CAPITAL MANAGEMENT LLC
4.75970%
STATE STREET CORP
STATE STREET CORP
3.36318%
WELLINGTON MANAGEMENT GROUP LLP
WELLINGTON MANAGEMENT GROUP LLP
2.68466%
VANGUARD PORTFOLIO MANAGEMENT LLC
VANGUARD PORTFOLIO MANAGEMENT LLC
2.37567%
GEODE CAPITAL MANAGEMENT, LLC
GEODE CAPITAL MANAGEMENT, LLC
...

Merck & Co Beneficial Ownership Filings (SEC 13D/G)

Free Float
99.8%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
39.99%
PANAMA MERGER SUB, INC.
PANAMA MERGER SUB, INC.
SEC ↗
27.50%
45-1540007
45-1540007
SEC ↗
27.50%
22-1918501
22-1918501
SEC ↗
19.96%
Merck & Co., Inc.
Merck & Co., Inc.
SEC ↗
14.90%
IMPERIAL BLUE CORPORATION
IMPERIAL BLUE CORPORATION
SEC ↗
12.60%
ARGON MERGER SUB, INC.
ARGON MERGER SUB, INC.
SEC ↗
11.40%
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
SEC ↗
11.40%
Merck Global Health Innovation Fund, LLC
Merck Global Health Innovation Fund, LLC
SEC ↗
9.90%
9.9%*
9.9%*
SEC ↗
9.90%
1,070,589 shares
1,070,589 shares
SEC ↗

Merck & Co Executives and Management Board

26 members · avg. age 61 · 38 % women

RD

Mr. Robert Davis (58)

Chairman of the Board, President, Chief Executive Officer · since 2014

23.19 M USD

Management

CG

Mr. Chirfi Guindo (59)

Senior Vice President, Chief Marketing Officer - Human Health

13.94 M USD
BL

Ms. Betty Larson (49)

Chief Human Resources Officer, Executive Vice President

11.26 M USD
DL

Dr. Dean Li (63)

Executive Vice President, President - Merck Research Laboratories · since 2021

10.09 M USD
RD

Mr. Richard Deluca (62)

Executive Vice President, President - Merck Animal Health

9.10 M USD
CL

Ms. Caroline Litchfield (56)

Chief Financial Officer, Executive Vice President

7.51 M USD
SC

Mr. Sanat Chattopadhyay (65)

Executive Vice President and President - Merck Manufacturing Division

6.24 M USD

Board of Directors

TG

Mr. Thomas Glocer (65)

Lead Independent Director

436,250.00 USD
PR

Dr. Paul Rothman (67)

Independent Director

413,750.00 USD
PC

Ms. Pamela Craig (68)

Independent Director

403,750.00 USD
CS

Dr. Christine Seidman (72)

Independent Director

375,000.00 USD
PR

Ms. Patricia Russo (72)

Independent Director

363,750.00 USD
RL

Dr. Risa Lavizzo-Mourey (70)

Independent Director

361,000.00 USD

Merck & Co Supply Chain

Merck & Co Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
30 companies
#Nameβ 1YTrend
1
AstraZeneca
Supplier·Customer·Pharmaceuticals·GB
0.66
0.24
0.94
0.78
0.77
0.73
0.88
#Nameβ 1YTrend
1
SUSE
Supplier·Software·LU
0.76
0.60
0.83
-0.13
0.04
—
—
2
DKSH Holding AG
Customer
0.67
—
—
—
—
—
—
3
908 Devices
Supplier·Electronic Equipment, Instruments & Components·US
0.61
0.36
0.60
-0.15
-0.36
—
—
4
Daiichi Sankyo Company, Limited
Supplier
0.60
0.35
0.46
0
0.05
—
—
5
Ono Pharmaceutical Co., Ltd.
Customer
0.47
0.35
—
—
—
—
—

Frequently asked questions about Merck & Co

The business model of Merck & Co Inc is centered around the development, manufacturing, and marketing of innovative pharmaceutical products and vaccines. Merck's primary aim is to improve and save lives by addressing unmet medical needs. Through rigorous research and development, the company focuses on discovering novel therapies and delivering them to patients worldwide. Merck operates across various therapeutic areas, including oncology, infectious diseases, vaccines, cardiovascular health, and more. By combining scientific expertise with a strong commitment to patients and healthcare professionals, Merck continually strives to advance medical science and make a positive impact on global health.

Merck & Co Inc is primarily active in the pharmaceutical and healthcare industries.

The main competitors of Merck & Co Inc in the market are Johnson & Johnson, Pfizer Inc, Novartis AG, and Bristol-Myers Squibb Company.

Merck & Co Inc is a renowned pharmaceutical company with a rich history and notable background. Established in 1891, Merck & Co Inc has been dedicated to enhancing global health and improving people's lives. The company has evolved into one of the leading players in the pharmaceutical industry, specializing in research, development, and manufacturing of innovative medications and vaccines. Merck & Co Inc has proactively contributed to medical advancements, from pioneering treatments for diseases like HIV/AIDS to addressing various health challenges. With a commitment to scientific excellence and patient well-being, Merck & Co Inc continues to shape the future of healthcare worldwide.

Merck & Co Inc, a leading pharmaceutical company, has achieved significant milestones throughout its history. The company's notable achievements include the development and launch of groundbreaking drugs like Gardasil, a vaccine for preventing cervical cancer, and Keytruda, an innovative immunotherapy for treating various types of cancer. Merck & Co Inc has also contributed to medical advancements with its research and development efforts, resulting in breakthroughs in areas such as HIV/AIDS treatment and vaccines. The company's commitment to improving global health has resulted in partnerships and initiatives aimed at tackling diseases like malaria and Ebola. Merck & Co Inc continues to make strides in the pharmaceutical industry, focusing on innovative solutions for unmet medical needs.

Merck & Co Inc is primarily present in several countries and regions across the world. The company has a strong global presence, with operations in the United States, Europe, Asia-Pacific, Latin America, and Africa. Merck & Co Inc has established a significant presence in key markets such as the United States, Germany, Japan, China, and Brazil. With its wide international footprint, Merck & Co Inc is committed to delivering its innovative healthcare solutions to patients and healthcare professionals worldwide.

Merck & Co Inc represents a strong commitment to scientific innovation, integrity, and improving global health. As a leading pharmaceutical company, Merck aims to discover, develop, and provide high-quality healthcare solutions. The company's corporate philosophy revolves around putting patients first, valuing diversity and inclusion, and taking responsibility for environmental sustainability. Merck is dedicated to delivering innovative medicines and vaccines, ensuring affordability and access for patients worldwide. With a focus on research, collaboration, and ethical business practices, Merck strives to make a positive impact on society and enhance the well-being of individuals around the globe.

Analysts currently set an average price target of 118.61 USD for the Merck & Co stock (median: 121.89 USD), implying -8.9 % versus the latest price. The consensus is based on 34 analyst ratings.

Merck & Co Analyst Price Targets 2026

34 analysts currently rate the Merck & Co stock: 21 recommend buying, 13 holding and 0 selling. For 2026, analysts expect Merck & Co to generate revenue of 66.80 B USD and earnings per share of 2.80 USD.

Merck & Co Analyst Price Targets 2026

Converted at the current exchange rate, the Merck & Co share trades at 114.26 EUR (131.84 USD).

The Merck & Co share (MRK) is listed on 11 stock exchanges, including: NYSE (MRK), XETRA (6MK.DE), Frankfurt (6MK.F), München (6MK.MU), Düsseldorf (6MK.DU), Hamburg (6MK.HM), London (0QAH.L), SIX (Zürich) (MRK1.SW).

Merck & Co Inc is one of the leading global pharmaceutical companies focused on the discovery, development, and marketing of drugs, vaccines, and biologics for a variety of diseases and disorders. The company is headquartered in Kenilworth, New Jersey and operates worldwide in over 140 countries.

The expected revenue of Merck & Co is 66.80 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Merck & Co is 6.96 B USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Merck & Co is currently 47.12. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Merck & Co stock.

The price-to-sales ratio (P/S) of Merck & Co is currently 4.91. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Merck & Co stock.

The Eulerpool Quality Score for Merck & Co is 6/10.

The ISIN of Merck & Co is US58933Y1055. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Merck & Co is A0YD8Q. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Merck & Co is MRK. The ticker symbol is used to trade Merck & Co shares on the stock exchange.

Over the past 12 months, Merck & Co paid a dividend of 3.28 USD . This corresponds to a dividend yield of about 2.49 %. For the coming 12 months, Merck & Co is expected to pay a dividend of 3.60 USD.

The current dividend yield of Merck & Co is 2.49 %.

Merck & Co pays a dividend, distributed in the months of , , , .

Merck & Co paid dividends every year for the past 36 years.

For the upcoming 12 months, dividends amounting to 3.60 USD are expected. This corresponds to a dividend yield of 2.76 %.

Merck & Co is assigned to the 'Health' sector.

To receive the latest dividend of Merck & Co from amounting to 0.85 USD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Merck & Co distributed 3.12 USD as dividends.

The dividends of Merck & Co are distributed in USD.

All fundamentals and in-depth analysis of Merck & Co

Our stock analysis for Merck & Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Merck & Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Merck & Co Stock
Merck & Co Revenue→
Merck & Co Stock
Merck & Co Net Income→
Merck & Co Stock
Merck & Co P/E→
Merck & Co Stock
Merck & Co P/S→
Merck & Co Stock
Merck & Co EBIT→
Merck & Co Stock
Merck & Co Dividend→
Merck & Co Stock
Merck & Co Directors Dealings→
Merck & Co Stock
Merck & Co Stocks→
Merck & Co Stock
Merck & Co Market capitalization→
Merck & Co Stock
Merck & Co Debt→
Merck & Co Stock
Merck & Co Liabilities→
Merck & Co Stock
Merck & Co Equity→
Merck & Co Stock
Merck & Co AAQS→
Merck & Co Stock
Merck & Co Employees→
Merck & Co Stock
Merck & Co ROE→
Merck & Co Stock
Merck & Co ROA→
Merck & Co Stock
Merck & Co ROCE→
Merck & Co Stock
Merck & Co News→
Merck & Co Stock
Merck & Co Analyst Price Targets→

Health Stocks

Merck KGaAMerchavia Holdings and InvestmentsMerck Tbk PTMercator MedicalMerdury BiopharmaceuticalMera PharmaceuticalsMereo BioPharma GroupMenticeMeridian BioscienceMental Health Technologies CoMerit Medical SystemsMenicon CoAll Stocks A–Z →